|本期目录/Table of Contents|

[1]马亮亮,阚通,赵仙先.肥厚型梗阻性心肌病不同间隔支行经皮腔内间隔支化学消融术的疗效观察[J].国际心血管病杂志,2016,01:54-57.
　MA Liangliang,KAN Tong,ZHAO Xianxian..Therapeutic effect of percutaneous transluminal septal myocardial ablation of different interval branches on hypertrophic obstructive cardiomyopathy[J].International Journal of Cardiovascular Disease,2016,01:54-57.
点击复制

肥厚型梗阻性心肌病不同间隔支行经皮腔内间隔支化学消融术的疗效观察(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年01期
页码:
54-57
栏目:
临床研究
出版日期:
2016-01-20

文章信息/Info

Title:
Therapeutic effect of percutaneous transluminal septal myocardial ablation of different interval branches on hypertrophic obstructive cardiomyopathy
作者:
马亮亮; 阚通; 赵仙先
200433上海,第二军医大学附属长海医院心内科
Author(s):
MA Liangliang; KAN Tong;  ZHAO Xianxian.
Shanghai Changhai Hospital Affiliated to the Second Military Medical University,Shanghai 200433,China
关键词:
肥厚型梗阻性心肌病; 经皮腔内间隔支化学消融术; 左室流出道压力阶差; 超声心动图
Keywords:
Hypertrophic obstructive cardiomyopathy;  Percutaneous transluminal septal myocardial ablation;  Left ventricle out-flow tract gredient;  Echocardiography
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.01.016
文献标识码:
-
摘要:
目的:探讨肥厚型梗阻性心肌病(hypertrophicobstructivecardiomyopathy,HOCM)不同间隔支行经皮腔内间隔支化学消融术(percutaneoustransluminalseptalmyocardialablation,PTSMA)的疗效。方法:入选30例HOCM患者,根据冠脉造影结果及需消融间隔支情况,分成消融第一间隔支、消融第二间隔支、消融第一、二间隔支3组,每组各10例,术中注入无水乙醇后经导管测量3组患者的左室流出道压力阶差(leftventricleout-flo
Abstract:
Objective: To evaluate the therapeutic effect of percutaneous transluminal septal myocardial ablation(PTSMA)of different interval branches on hypertrophic obstructive cardiomyopathy(HOCM).Methods: Thirty patients who were diagnosed as HOCM were admitted t

参考文献/References

[1] 刘榜霞,李小荣,杜 为,等.合并高血压的肥厚型梗阻性心肌病患者的临床特点[J].国际心血管杂志,2014,41(3):195-197.
[2] Hwang HJ,Choi EY,Kwan J,et al.Dynamic change of mitral apparatus as potential cause of left ventricular outflow tract obstruction in hypertrophic cardiomypathy[J].Eur J Echocardiogy,2012,12(1):19-25.
[3] Khouzam RN,Naidu SS.Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J].Curr Cardiol Rep,2014,16(5):478.
[4] Yue-Cheng H,Zuo-Cheng L,Xi-Ming L,et al.Long-term follow-up impact of dual-chamber pacing on patierts with hypertrophic obstrcutive cardiomyopathy[J].Pacing Clin Electrophysiol,2013,36(1):86-93.
[5] Lucon A,Palud L,Pavin D,et al.Very late effects of dual chamber pacing therapy for obstrctive hypertrophic cardiomyopathy[J].Arch Cardiovasc Dis,2013,106(6):373-381.
[6] Qintar M,Morad A,Alhawasli H,et al.Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy[J].Cochrane Datebase Syst Rev,2012,5:CD008523.
[7] Parry DJ,Raskin RE,Poynter JA,et al.Short and medium term outcomes of surgery fo patients with hypertrophic obstrctive cardiomyopathy[J].Ann Thorac Surg,2015,99(4):1213-1219.
[8] Furukawa K,Hayase T,Yano M,et al.Mitral valve replacement and septal myectomy for hypertrophic obstructive cardiomyopahty[J].Gen Thorac Cariodiovasc Surg,2014,62(3):181-183.
[9] Geske JB,Konecny T,Ommen SR,et al.Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy[J].Eur Heart J,2014,35(30):2032-2039.
[10] 王颍骅,薛 松.肥厚型梗阻性心肌病的外科治疗[J].国际心血管病杂志,2014,41(5):324-326.
[11] Zeng Z,Wang F,Dou X,et al.Comparison of percutaneous transluminal septal myocardial ablation vesus septalmyectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy-a meta analysis[J].Int J Cardiol,2006,112(1):80-84.
[12] Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet, 1995, 346(8969):211-214.
[13] Maron BJ,Spirito P,Ackerman MJ,et al.Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy[J].J Am Coll Cardiol,2013,61(14):1521-1535.
[14] Jassal DS,Neilan TG,Fifer MA,et al.Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J].Eur Heart J,2006,27(15):1805-1810.
[15] Jensen MK, Havndrup O, Hassager C, et al. Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy[J]. Scand Cardiovasc J, 45(3):153-160.
[16] Seqqewiss H,Gleichmann U,Faber L,et al.Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy:acute results and 3-month follow-up in 25 patients[J].J Am Coll Cardiol,1998,31(2):252-258.

备注/Memo

备注/Memo:
基金项目:国家自然基金面上项目(81370266) 作者单位:200433上海,第二军医大学附属长海医院心内科 通信作者:赵仙先,Email:13601713431@163.com
更新日期/Last Update: 2016-01-20